CogniSci Labs Inc

At CogniSci Labs, we are transforming the future of neurodegenerative disease diagnostics with a groundbreaking platform technology. Our AI-powered, non-invasive saliva-based tests detect cfDNA methylation patterns, enabling earlier and more accurate detection of conditions like Alzheimer’s, Parkinson’s, and other brain-related disorders. By making diagnostic tests easy, accessible, and cost-effective, we aim to improve patient outcomes through earlier intervention and personalized care. Current diagnostic methods such as blood tests, brain scans, and cognitive evaluations are costly, invasive, and often ineffective for early-stage detection. Our platform technology changes that. With a simple at-home saliva collection kit, patients can detect neurodegenerative diseases far earlier than ever before, even before symptoms fully manifest. Our tests provide data-rich insights that help doctors tailor treatment plans sooner, making early treatment a reality. CogniSci Labs isn’t just about solving one problem—we’re building a platform that can be adapted to a wide range of neurological conditions. By analyzing cfDNA methylation patterns, our technology has the potential to revolutionize the way we diagnose and monitor diseases like ALS, traumatic brain injury (TBI), and even autoimmune disorders. This adaptability makes our platform a powerful tool for both clinical diagnostics and wellness monitoring. We are also developing a consumer-facing wellness version of our dementia test, targeting launch in Q1 2025, empowering individuals to proactively monitor their cognitive health. Our technology not only serves healthcare providers but also enables individuals to take control of their health with early, actionable data. Backed by scientific rigor and partnerships with leading research organizations, CogniSci Labs is positioned to become a leader in the next generation of neurodegenerative diagnostics, delivering innovative, scalable solutions for a healthier future.